Relevant Dermatoses Among U.S. Military Service Members: An ...

New York Reports 1st US Polio Case In Nearly A Decade

NEW YORK (AP) — An unvaccinated young adult from New York recently contracted polio, the first U.S. Case in nearly a decade, health officials said Thursday.

Officials said the patient, who lives in Rockland County, had developed paralysis. The person developed symptoms a month ago and did not recently travel outside the country, county health officials said.

It appears the patient had a vaccine-derived strain of the virus, perhaps from someone who got live vaccine — available in other countries, but not the U.S. — and spread it, officials said.

The person is no longer deemed contagious, but investigators are trying to figure out how the infection occurred and whether other people were exposed to the virus.

Most Americans are vaccinated against polio, but this should serve as a wake-up call to the unvaccinated, said Jennifer Nuzzo, a Brown University pandemic researcher.

"This isn't normal. We don't want to see this," Nuzzo said. "If you're vaccinated, it's not something you need to worry about. But if you haven't gotten your kids vaccinated, it's really important that you make sure they're up to date."

Health officials scheduled vaccination clinics in New York for Friday and Monday, and encouraged anyone who has not been vaccinated to get the shots.

"We want shots in the arms of those who need it," Rockland County Health Commissioner Dr. Patricia Schnabel Ruppert said at a Thursday news conference.

Polio was once one of the nation's most feared diseases, with annual outbreaks causing thousands of cases of paralysis. The disease mostly affects children.

Vaccines became available starting in 1955, and a national vaccination campaign cut the annual number of U.S. Cases to less than 100 in the 1960s and fewer than 10 in the 1970s, according to the Centers for Disease Control and Prevention.

In 1979, polio was declared eliminated in the U.S., meaning there was no longer routine spread.

GAZETTE COVERAGE Ensure access to everything we do, today and every day, check out our subscribe page at DailyGazette.Com/Subscribe

Rarely, travelers have brought polio infections into the U.S. The last such case was in 2013, when a 7-month-old who had recently moved to the U.S. From India was diagnosed in San Antonio, Texas, according the federal health officials. That child also had the type of polio found in the live form of vaccine used in other countries.

There are two types of polio vaccines. The U.S. And many other countries use shots made with an inactivated version of the virus. But some countries where polio has been more of a recent threat use a weakened live virus that is given to children as drops in the mouth. In rare instances, the weakened virus can mutate into a form capable of sparking new outbreaks.

U.S. Children are still routinely vaccinated against polio with the inactivated vaccine. Federal officials recommend four doses: to be given at 2 months of age; 4 months; at 6 to 18 months; and at age 4 through 6 years. Some states require only three doses.

According to the CDC's most recent childhood vaccination data, about 93% of 2-year-olds had received at least three doses of polio vaccine.

Polio spreads mostly from person to person or through contaminated water. It can infect a person's spinal cord, causing paralysis and possibly permanent disability and death.

Polio is endemic in Afghanistan and Pakistan, although numerous countries in Africa, the Middle East and Asia have also reported cases in recent years.

Rockland County, in New York City's northern suburbs, has been a center of vaccine resistance in recent years. A 2018-2019 measles outbreak there infected 312 people.

Last month, health officials in Britain warned parents to make sure children have been vaccinated because the polio virus had been found in London sewage samples. No cases of paralysis were reported.

More: All News GAZETTE COVERAGE Ensure access to everything we do, today and every day, check out our subscribe page at DailyGazette.Com/Subscribe

Categories: -News-

Two CJD Victims Linked To The Same Polio Vaccine

by SEAN POULTER, Daily Mail

Two youngsters who contracted the human form of mad cow disease received the same polio vaccination derived from calf foetuses, government scientists revealed.

The extraordinary coincidence has raised the prospect that millions of people who received the vaccine in the late 1980s and 1990s could be at risk.

Experts on the Government's BSE advisory committee, SEAC, insisted there was no cause for alarm and described the risks as 'infinitesimally small'.

However families who have lost loved ones to the appalling condition said the history of BSE had been littered with bogus reassurances and blunders.

The fact that two youngsters had received the same vaccination emerged as experts investigated five cases of vCJD in the Southampton area.

They were among 80,000 people to be vaccinated from the same delivery of polio vaccine. A further six million were vaccinated from material derived from the same specific source.

And as many as 60million doses of vaccine created from cow foetuses have been given to Britons over the years.

Medical experts had told the Government that no such serum should be used from British cows after 1989.

However last year it emerged that a loophole in the system meant that it continued to be administered.

In fact, vaccine derived from British cows went on being used right up until last year, when the Department of Health finally discovered the loophole and recalled the product.

Failures in the accurate collection of medical records mean that it is impossible to know precisely which other children and adults received vaccine from the same batch.

Similarly, it is almost impossible to know whether the more than 100 victims of human BSE identified so far were given the same vaccine.

Most babies are given the polio inoculation within the first six months of life, there is a booster at around the age of four and teenagers get another booster on leaving school.

The two youngsters are part of a cluster of five people from the Southampton area who have developed the disease.

One was given the vaccine shortly before leaving school and the other by medical staff at a further education college in the city - most probably on a sugar lump - in late 1994.

Experts on SEAC said there may have been other possible, but so far undiscovered links, between the youngsters.

Both were diagnosed in the last two years and the vaccine connection was subsequently discovered by an investigation of their lifestyles, eating habits and upbringing.

The chairman of SEAC, Professor Peter Smith, played down the connection, suggesting it was a coincidence rather than evidence of a link to the vaccine.

'We are not linking the vaccine to these two cases, ' he said. 'These are two cases who happened to receive this batch of vaccine.

'These cases were identified because there were five in the Southampton area.

'They were intensively investigated and one of the things discovered was that they received the same batch of vaccine.

'The simple fact that they lived in the same area meant they were likely to have had vaccine from the same batch. There may have been other similarities.

'The vaccine is generally given to infants, but quite a lot of us are given the vaccine at later ages, as happened with these individuals.'

The vaccine was made by Wellcome, now part of the Glaxo-SmithKline pharmaceutical giant, at laboratories in Bromley, Kent, in the late 1980s.

Subsequently the vaccine was sold to a company called Medeva which distributed it to the NHS under the brand name Evans.

Professor Smith said the Department of Health would have to answer for the fact that the cow serum vaccine continued to be used after a ban was recommended.

Frances Hall, of the Human BSE Foundation, who lost her 21-year-old son Peter to the disease, questioned the reliability of official assurances.

'Sadly, throughout the history of BSE the public have been given assurances which turned out to be wrong,' she said.

'Everything, including the fact that BSE can spread to humans, has been a theoretical possibility until it has been proven, by which time the damage has been done.

'This needs to be investigated very closely. Who knows whether this is a coincidence or not, it is too soon to say.

'Quite how a government can think it has banned this vaccine only to discover it is still being used more than five years later is unbelievable.'

Dr Deirdre Cunningham, the director of public health for Lam-beth, Southwark and Lewisham and a member of the SEAC committee, said it was vital that parents were not put off vaccinating their children against polio and other illnesses.

{"status":"error","code":"499","payload":"Asset id not found: readcomments comments with assetId=90590, assetTypeId=1"}

Polio Vaccine Market Size, Industry Report And Forecast To 2030

The global "Polio Vaccine Market" report offers valuable insights into the latest industry trends combined within 98 of informative Pages. It also conducts a comprehensive analysis, encompassing the worldwide market size, regional and national market dimensions, growth patterns, market share, competitive landscape, sales analysis, and the influence of both domestic and international leading players [ CSL Limited, Astellas Pharma, MedImmune, Merck, GlaxoSmithKline, etc.] in the Polio Vaccine industry. Additionally, it explores topics such as optimizing the value chain, examining trade regulations, recent developments, opportunities assessment, strategic market growth analysis, product launches, expanding market presence, and technological innovations. Through its thorough examination of these elements, the report serves as a trustworthy resource for gaining a clear understanding of the current state of the Polio Vaccine Market and identifying potential avenues for growth and advancement.

Get A Sample PDF Of The Report At -https://www.Industryresearch.Co/enquiry/request-sample/22365122

The global Polio Vaccine market size was valued at USD 225.33 million in 2022 and is expected to expand at a CAGR of 0.48 Percentage during the forecast period, reaching USD 231.91 million by 2028.

For the competitive landscape, the report also introduces the industry players from the perspective of market share, concentration index, etc., and outlines the leading companies in detail, with which readers can get a better idea of your competitors and gain a deep understanding of the competitive situation. In addition, mergers and acquisitions, emerging market trends, the impact of COVID-19, and regional conflicts will be considered.

List Of Key Companies Operating In Polio Vaccine Market:

CSL Limited

Astellas Pharma

MedImmune

Merck

GlaxoSmithKline

JohnsonandJohnson

Emergent BioSolutions

Get Sample Copy of Polio Vaccine Market Report

Global Polio Vaccine Market: Segment Analysis

The report not only predicts the growth in revenue but also conducts an analysis of the current trends in each of the sub-categories spanning from 2017 to 2030. Industry Research has segmented the global Polio Vaccine market report on the basis of product, application, and regions for this study.

Most Important Types Of Polio Vaccine Products Covered In This Report Are:

Inactivated Polio Vaccine (IPV)

Oral Polio Vaccine (OPV)

Most Widely Used Downstream Fields Of Polio Vaccine Market Covered In This Report Are:

Public

Private

Regional Overview

The worldwide Polio Vaccine market has been categorized based on geography, with North America, Europe, Asia Pacific, Latin America, and Middle East and Africa being the key regions. These regions have been further segmented into countries and sub-regions. These various countries and sub-regions focused in this market report are U.S., Canada and Mexico in North America, Brazil, Argentina and Rest of South America as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Inquire Or Share Your Questions If Any Before The Purchasing This Report -https://www.Industryresearch.Co/enquiry/pre-order-enquiry/22365122

The Polio Vaccine Report Offers A Range Of Valuable Insights And Information, Including:

Comprehensive Analysis: The report provides a thorough analysis of the subject matter, presenting a detailed examination of various aspects related to the topic.

Market Competition: It evaluates the competitive landscape within the industry, highlighting key players, their strategies, and market positioning.

Growth Factors: The report identifies and analyzes the factors driving growth in the market, helping businesses understand the key drivers of success.

Restraints: It also examines the challenges and restraints that may impact the market, offering a holistic view of potential obstacles and risks.

Business Projections: The report presents projections and forecasts for the business, enabling stakeholders to anticipate future trends and plan accordingly.

Target Market Perspective: It offers insights into the target market, including consumer preferences, demands, and behavior, helping businesses tailor their strategies to effectively meet customer needs.

Best Practices: The report suggests industry best practices that businesses can adopt to enhance their operations and achieve profitability.

Industry Metrics: It provides relevant enterprise metrics, such as industry developments, market size, trends, and future opportunities, assisting organizations in making informed decisions.

Overall, the report serves as a valuable resource, equipping readers with a comprehensive understanding of the subject matter and facilitating strategic decision-making.

What Makes This Polio Vaccine Market Report Worth Purchasing?

The report gives drivers, limitations, and openings on the lookout

Impact of Covid-19 available

What makes this market attractive?

What is the CAGR of the market?

Commonly Asked Questions:

What is the purpose of the report? 2. What does the report cover? 3. How does the report help businesses? 4. What are some key features of the report? 5. Can the report help in decision-making? 6. Are there industry metrics included in the report? 7. Who can benefit from the report?

Click The Link Below To Understand How COVID-19/ Russia-Ukraine War Impact On The Polio Vaccine Market https://www.Industryresearch.Co/enquiry/request-covid19/22365122

TOC Of The Polio Vaccine Market Is As Follows:

1 Polio Vaccine Market Overview1.1 Product Overview 1.2 Market Segmentation 1.2.1 Market by Types 1.2.2 Market by Applications 1.2.3 Market by Regions 1.3 Global Polio Vaccine Market Size (2018-2028) 1.3.1 Global Polio Vaccine Revenue (USD) and Growth Rate (2018-2028) 1.3.2 Global Polio Vaccine Sales Volume and Growth Rate (2018-2028) 1.4 Research Method and Logic 1.4.1 Research Method 1.4.2 Research Data Source2 Global Polio Vaccine Market Historic Revenue (USD) and Sales Volume Segment by Type2.1 Global Polio Vaccine Historic Revenue (USD) by Type (2018-2023)2.2 Global Polio Vaccine Historic Sales Volume by Type (2018-2023)2.3 Type 1 Sales and Price (2018-2023)2.4 Type 2 Sales and Price (2018-2023)3 Global Polio Vaccine Historic Revenue (USD) and Sales Volume by Application (2018-2023)3.1 Global Polio Vaccine Historic Revenue (USD) by Application (2018-2023)3.2 Global Polio Vaccine Historic Sales Volume by Application (2018-2023)3.3 Application 1 Sales, Revenue and Growth Rate (2018-2023)3.4 Application 2 Sales, Revenue and Growth Rate (2018-2023)4 Market Dynamic and Trends4.1 Industry Development Trends under Global Inflation4.2 Impact of Russia and Ukraine War4.3 Driving Factors for Polio Vaccine Market4.4 Factors Challenging the Market4.5 Opportunities4.6 Risk Analysis4.7 Industry News and Policies by Regions4.7.1 Polio Vaccine Industry News4.7.2 Polio Vaccine Industry Policies5 Global Polio Vaccine Market Revenue (USD) and Sales Volume by Major Regions5.1 Global Polio Vaccine Sales Volume by Region (2018-2023) 5.2 Global Polio Vaccine Market Revenue (USD) by Region (2018-2023)6 Global Polio Vaccine Import Volume and Export Volume by Major Regions6.1 Global Polio Vaccine Import Volume by Region (2018-2023) 6.2 Global Polio Vaccine Export Volume by Region (2018-2023)7 North America Polio Vaccine Market Current Status (2018-2023)7.1 Overall Market Size Analysis (2018-2023) 7.1.1 North America Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 7.1.2 North America Polio Vaccine Sales Volume and Growth Rate (2018-2023) 7.2 North America Polio Vaccine Market Trends Analysis Under Global Inflation 7.3 North America Polio Vaccine Sales Volume and Revenue (USD) by Country (2018-2023) 7.4 United States 7.4.1 United States Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 7.5 Canada7.5.1 Canada Polio Vaccine Revenue (USD) and Growth Rate (2018-2023)8 Asia Pacific Polio Vaccine Market Current Status (2018-2023)8.1 Overall Market Size Analysis (2018-2023) 8.1.1 Asia Pacific Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 8.1.2 Asia Pacific Polio Vaccine Sales Volume and Growth Rate (2018-2023) 8.2 Asia Pacific Polio Vaccine Market Trends Analysis Under Global Inflation 8.3 Asia Pacific Polio Vaccine Sales Volume and Revenue (USD) by Country (2018-2023) 8.4 China 8.4.1 China Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 8.5 Japan 8.5.1 Japan Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 8.6 India 8.6.1 India Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 8.7 South Korea 8.7.1 South Korea Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 8.8 Southeast Asia 8.8.1 Southeast Asia Polio Vaccine Revenue (USD) by Country (2018-2023) 8.9 Australia 8.9.1 Australia Polio Vaccine Revenue (USD) and Growth Rate (2018-2023)

Purchase This Report (Price 3250 USD For A Single-User License) https://www.Industryresearch.Co/purchase/22365122

9 Europe Polio Vaccine Market Current Status (2018-2023) 9.1 Overall Market Size Analysis (2018-2023) 9.1.1 Europe Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 9.2.1 Europe Polio Vaccine Sales Volume and Growth Rate (2018-2023) 9.2 Europe Polio Vaccine Market Trends Analysis Under Global Inflation 9.3 Europe Polio Vaccine Sales Volume and Revenue (USD) by Country (2018-2023) 9.4 Germany 9.4.1 Germany Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 9.5 France 9.5.1 France Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 9.6 United Kingdom 9.6.1 United Kingdom Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 9.7 Italy 9.7.1 Italy Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 9.8 Spain 9.8.1 Spain Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 9.9 Russia 9.9.1 Russia Polio Vaccine Revenue (USD) and Growth Rate (2018-2023) 9.10 Poland 9.10.1 Poland Polio Vaccine Revenue (USD) and Growth Rate (2018-2023)10 Latin America Polio Vaccine Market Current Status (2018-2023)10.1 Overall Market Size Analysis (2018-2023)10.1.1 Latin America Polio Vaccine Revenue (USD) and Growth Rate (2018-2023)10.1.2 Latin America Polio Vaccine Sales Volume and Growth Rate (2018-2023)10.2 Latin America Polio Vaccine Market Trends Analysis Under Global Inflation10.3 Latin America Polio Vaccine Sales Volume and Revenue (USD) by Country (2018-2023)10.4 Mexico10.4.1 Mexico Polio Vaccine Revenue (USD) and Growth Rate (2018-2023)10.5 Brazil10.5.1 Brazil Polio Vaccine Revenue (USD) and Growth Rate (2018-2023)10.6 Argentina10.6.1 Argentina Polio Vaccine Revenue (USD) and Growth Rate (2018-2023)11 Middle East and Africa Polio Vaccine Market Current Status (2018-2023)11.1 Overall Market Size Analysis (2018-2023)11.1.1 Middle East and Africa Polio Vaccine Revenue (USD) and Growth Rate (2018-2023)11.2.1 Middle East and Africa Polio Vaccine Sales Volume and Growth Rate (2018-2023)11.2 Middle East and Africa Polio Vaccine Market Trends Analysis Under Global Inflation11.3 Middle East and Africa Polio Vaccine Sales Volume and Revenue (USD) by Country (2018-2023)11.4 GCC Countries11.4.1 GCC Countries Polio Vaccine Revenue (USD) and Growth Rate (2018-2023)11.5 Africa11.5.1 Africa Polio Vaccine Revenue (USD) and Growth Rate (2018-2023)12 Market Competition Analysis and Key Companies Profiles12.1 Market Competition by Key Players12.1.1 Global Polio Vaccine Revenue (USD) and Market Share of Key Players12.1.2 Global Polio Vaccine Sales Volume and Market Share of Key Players12.1.3 Global Polio Vaccine Average Price by Players12.1.4 Mergers and Acquisitions, Expansion 13 Value Chain of the Polio Vaccine Market 14 New Project Feasibility Analysis14.1 Industry Barriers and New Entrants SWOT Analysis14.2 Analysis and Suggestions on New Project Investment15 Global Polio Vaccine Market Revenue (USD) and Sales Volume Forecast Segment by Type, Application and Region15.1 Global Polio Vaccine Revenue (USD) and Sales Volume Forecast by Type (2023-2028)15.1.1 Global Polio Vaccine Revenue (USD) Forecast by Type (2023-2028)15.1.2 Global Polio Vaccine Sales Volume Forecast by Type (2023-2028)15.2 Global Polio Vaccine Revenue (USD) and Sales Volume Forecast by Application (2023-2028)15.2.1 Global Polio Vaccine Revenue (USD) Forecast by Application (2023-2028)15.2.2 Global Polio Vaccine Sales Volume Forecast by Application (2023-2028)15.3 Global Polio Vaccine Sales Volume Forecast by Region (2023-2028)15.4 Global Polio Vaccine Revenue (USD) Forecast by Region (2023-2028)16 Research Findings and Conclusion

For More About TOC - https://www.Industryresearch.Co/TOC/22365122#Tables?Utm_source=Ben_FKWM_ANGAD

Contact Us:

Industry Research Phone: US +1 424 253 0807 UK +44 203 239 8187Email: sales@industryresearch.CoWeb: https://www.Industryresearch.Co

COMTEX_441337961/2598/2023-10-03T00:29:53

© 2023 Benzinga.Com. Benzinga does not provide investment advice. All rights reserved.

---